Document is current
Any future updates will be listed below
-
Authors
McLouth, Laurie E. https://orcid.org/0000-0002-4888-6520
Zheng, Yue
Smith, Stephanie
Hodi, F. Stephen
Rao, Uma N.
Cohen, Gary I.
Amatruda, Thomas T.
Dakhil, Shaker R.
Curti, Brendan D.
Nakhoul, Ibrahim
Chandana, Sreenivasa R.
Bane, Charles L.
Marinier, David E.
Lee, Sandra J.
Sondak, Vernon K.
Kirkwood, John M.
Tarhini, Ahmad A.
Wagner, Lynne I.
-
Funding
Funding for this research was provided by:
ECOG-ACRIN Cancer Research Group (UG1CA233184, U10CA180794, UG1CA189823, U10CA180821, UG1CA189828, U10CA180820, UG1CA189867, U10CA180868, UG1CA189974, U10CA180888, UG1CA189860, UG1CA189863, UG1CA189953, UG1CA189956, UG1CA189957, UG1CA233180, UG1CA233196, UG1CA189858)
National Cancer Institute (R25CA122061, P30 CA1777558, L30CA231709)
National Center for Clinical and Translational Science (2KL2TR001996-05A1)
- License Information
-
More Information
Article History
Accepted: 2 August 2022
First Online: 27 August 2022
Declarations
:
: <i>FSH</i>: Stock and Other Ownership Interests: Apricity; Torque Consulting or Advisory Role: Merck Sharp & Dohme, Novartis, Genentech/Roche, EMD Serono, Sanofi, Bayer, Aduro Biotech, Pfizer, Verastem, Bristol-Myers Squibb, Takeda Pharmaceuticals, Surface, Compass Therapeutics, Partners Therapeutics, Pionyr, 7Hills Pharma, Torque, and Rheos; Research Funding: Bristol-Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Genentech/Roche (Inst), and Novartis (Inst) Patents; Royalties and Other Intellectual Property: Patent pending as per institutional policy; patent-pending royalties received on MICA-related disorder application to institution per institutional IP policy; angiopoietin-2 biomarkers predictive of anti-immune checkpoint response (Inst); compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms; and methods of using pembrolizumab and trebananib (Inst); Travel, Accommodations, and Expenses: Novartis, Bristol-Myers Squibb; Other Relationship: Bristol-Myers Squibb and Genentech/Roche; <i>GIC</i>: Stock and Other Ownership Interests: Nymox, Celgene, AbbVie; Honoraria: Amgen; <i>SJL</i>: Stock and Other Ownership Interests: NantKwest (I); Consulting or Advisory Role: Roche/Genentech; <i>VKJ</i>: Consulting or Advisory Role: Merck/Schering-Plough, Novartis, Bristol-Myers Squibb, Array BioPharma, Genentech/Roche, Pfizer, Polynoma, Regeneron, and Replimune; <i>JMK</i>: Consulting or Advisory Role: Bristol-Myers Squibb, Novartis, Array BioPharma, Immunocore, Iovance, Elsevier, Checkmate Pharmaceuticals (Inst), Bristol-Myers Squibb (Inst), Immunocore (Inst), and Merck (Inst); Research Funding: Merck (Inst), Prometheus Laboratories (Inst), and Immunocore (Inst); <i>AAT</i>: Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Genentech/Roche, Incyte, Newlink Genetics, Array BioPharma, Novartis, OncoSec, HUYA Bioscience International, Immunocore, Pfizer/EMD Serono, Sanofi/Regeneron, and BioNTech; Research Funding: Incyte (Inst), Prometheus Laboratories (Inst), Bristol-Myers Squibb (Inst), Amgen (Inst), Incyte (Inst), Novartis (Inst), GreenPeptide (Inst), and Merck (Inst). No other potential conflicts of interest were reported.
: The protocol was approved by the Institutional Review Boards at each registering institution. Written informed consent was obtained from all patients.
: Not applicable.
